medical corporation type private industry biopharmaceutical founded 1998 headquarters omaha nebraska key people dr. jeeri r. reddy founder president & ceo products vaccines diagnostics subsidiaries jni medical corporation coted ivoire website http www.jn vaccines.com jn international medical corporation jnimc is a u.s. based biopharmaceutical corporation which since 1998 has been focused on developing vaccines and diagnostics for infectious disease for developing countries . this private corporation formerly known as jeeri neotech international inc was founded in 1998 by dr. jeeri r. reddy with the help of dr. kelly f. lechtenberg in a small rural town oakland nebraska . from there it grew and expanded until in the year 2000 the corporation moved to omaha nebraska . jnimc partners with global health organizations such as the clinton global initiative 1 the global business coalition new york president s malaria initiative pmi 2 3 the global health council ngos local governments and communities in developing countries to address the health issues related to hiv aids malaria tuberculosis and bacterial meningitis that affect the underserved communities in west africa south east asia and latin america . contents 1 history 2 vaccine facilities 3 acquisition 4 clinical trials 5 research and development 6 patents and publications 7 references 8 external links history edit early in its existence jnimc developed rapid and western blot 4 diagnostic test kits for malaria tb and hiv . jni was the first company to screen about 2 million pregnant women for the presence of hiv in south east asia from 1999 2002 . this resulted in many hiv free births because the hospitals were able to treat the hiv positive pregnant women with antiretroviral drugs . a rapid tuberculosis test was developed by the company and demonstrated its diagnostic potential by screening 400 tb positive and negative serum samples from various hospitals in india . the results showed that the combination of mycobacterium tuberculosis antigens improved the diagnostic specificity and sensitivity of the tests . 5 the diagnostic products of the company have been used in more than 30 countries for screening infectious diseases . vaccine facilities edit jnimc facility was designed for manufacture research and development of human vaccines in compliance with fda compliant cgmp current good manufacturing practices and european union good manufacturing practice standards . the facility has fermentation formulation vial freeze drying bacterial facilities classified as biosafety level 2 cdc nih bl2 ls and iso 9001 . the facility includes both the upstream and downstream operations when the fermentation process is scaled up for bacterial polysaccharide product development . the facilities were designed for manufacture of vaccines in compliance with cgmp and european standards . the facility has fermentation formulations and lyophilization and handling of bacterial polysaccharide products . utilities include water for injection grade water wfi system oil free compressed air system usp clean steam system process chilled system and clean in place systems . processes include ; seed bank media preparation fermentation cell harvest centrifugation and purification including ultra filtration . the facility operates with scada supervisory control and data acquisition generally refers to industrial control systems ics . jnimc s cgmp vaccine facility spans 32 000 ft and will include a 10 000 ft fully automated unit . the facility has a targeted production of 10 million doses of vaccine annually . cgmp vaccine facility . cgmp facility inside . 1000 liters bioreactors . vialing station . acquisition edit in january 2009 jnimc acquired biocor vaccine manufacture facilities a subsidiary of pfizer inc. in omaha . 6 the state of the art facilities consist of three buildings approximately 71 749 sq. ft. and were designed for manufacture of vaccines in compliance with european community u.s. food and drug administration and u.s. department of agriculture standards . jnimc will keep the starwood containment facility for research and development of vaccines for clinical studies and moved its vaccine operations to the newly acquired maple street facilities in february 2009 . the added capacity of the plant allowed increased production of the firm s meningitis vaccine . the investment in the new facility plant is the largest capital investment in omaha to date for the company and will result in production formulation filling and packaging capacity facilities which are intended to help significantly reduce time to market for the firm s meningococcal meningitis serotypes a c y & w 135 vaccine production capacity to meet the demand of sub saharan africa . clinical trials edit meningococcal meningitis diphtheria conjugate vaccine nmvac4 a c y w 135 dt meningococcal meningitis diphtheria conjugate vaccine for the prevention of meningococcal meningitis serogroups a c y and w 135 diphtheria conjugate vaccine . phase 1 and 2 human clinical trials completed in california and maryland with ind approval from food and drug administration fda 7 and 8 research and development edit vaccine phase action ischemic stroke pre clinical development for the prevention and therapy for transient ischemic attack tia epilepsy and transient ischemic stroke . genital herpes pre clinical development for the prevention of genital herpes . alzheimer pre clinical development for the prevention and therapy for alzheimer s disease . patents and publications edit jnimc patents and publishes journal articles of its research and technologies in the field of human infectious diseases and neurological disorders 5 9 10 11 12 13 14 patents by inventor jeeri r reddy 15 references edit clinton global initiative development and production of low cost vaccines 2006 https www.clintonfoundation.org clinton global initiative commitments development and production low cost vaccines http jn vaccines.org pmi.htm http www.pmi.gov pirkko soundy and bronwen harvey . rapley ralph ; walker john h. eds . 2005 . medical biomethods handbook . humana press . pp. 53 55 http www.clinchem.org content 52 4 790 . full . cs1 maint multiple names authors list link a b reddy jr kwang j lechtenberg kf khan nc prasad rb chengappa mm january 2002 . an immunochromatographic serological assay for the diagnosis of mycobacterium tuberculosis . comparative immunology microbiology and infectious diseases . 25 1 21 7 . doi 10.1016 s0147 9571 01 00016 9 . pmid 11831744 . omaha world herald . friday january 30 2009 . jnimc acquires vaccine facilities from pfizer inc. http www.mmdnewswire.com jn international 4537.html https clinicaltrials.gov ct2 show nct01482052 term meningococcal meningitis & rank 1 https clinicaltrials.gov ct2 show nct01897402 term jn international & rank 1 jeeri r reddy . method of producing meningococcal meningitis vaccine for neisseria meningitidis serotypes a c y and w 135 . united states patent office uspto http patft.uspto.gov netacgi nph parser sect1 pto2 & sect2 hitoff & p 1 & u % 2fnetahtml % 2fpto % 2fsearch bool.html & r 1 & f g & l 50 & co1 and & d ptxt & s1 % 22reddy jeeri % 22 & os jeeri r. reddy . preventive and therapeutic vaccine for stroke and neurological disorders . http appft.uspto.gov netacgi nph parser sect1 pto2 & sect2 hitoff & p 1 & u % 2fnetahtml % 2fpto % 2fsearch bool.html & r 2 & f g & l 50 & co1 and & d pg01 & s1 % 22jeeri r reddy % 22 & os jeeri r. reddy preventive and therapeutic vaccine for huntington s disease http appft.uspto.gov netacgi nph parser sect1 pto2 & sect2 hitoff & p 1 & u % 2fnetahtml % 2fpto % 2fsearch bool.html & r 3 & f g & l 50 & co1 and & d pg01 & s1 % 22jeeri r reddy % 22 & os jeeri r reddy . preventive and therapeutic vaccine for alzheimer s disease . http appft.uspto.gov netacgi nph parser sect1 pto2 & sect2 hitoff & p 1 & u % 2fnetahtml % 2fpto % 2fsearch bool.html & r 4 & f g & l 50 & co1 and & d pg01 & s1 % 22jeeri r reddy % 22 & os reddy jeeri . preventive and therapeutic vaccine for stroke and neurological disorders http www.wipo.int pctdb en wo.jsp wo 2008121146 reddy jr kwang j varthakavi v lechtenberg kf minocha hc october 1999 . semiliki forest virus vector carrying the bovine viral diarrhea virus ns3 p80 cdna induced immune responses in mice and expressed bvdv protein in mammalian cells . comparative immunology microbiology and infectious diseases . 22 4 231 46 . doi 10.1016 s0147 9571 99 00014 4 . pmid 10465327 . http patents.justia.com inventor jeeri r reddy external links edit jn international medical corporation official web site . retrieved from https en.wikipedia.org w index.php title jn international medical corporation & oldid 731964494 categories biotechnology companies of the united statesmultinational companies headquartered in the united statesvaccine producershidden categories cs1 maint multiple names authors listpages using infobox company with unsupported parameters navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages add links this page was last modified on 28 july 2016 at 17 45 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view